News and Announcements
Phylogica Limited (ASX: PYC) set to reach experimental milestone
- Published July 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Phylogica Limited (ASX: PYC) is expected to complete their experience of delivering Cre Cargo into the nucleus cells in multiple tissues in live animals.
- The success of the delivery will represent a significant milestone for the company, transitioning them from proof of concept to therapeutic cargoes.
Phylogica (ASX: PYC) has announced that their experimental timelines are on track. The company will deliver the Cre cargo (enzyme) into the nucleus cells in multiple tissues in a live animal in July 2018. Phylogica’s core asset is their structurally diverse drug library which the company has chosen to use in identifying Cell Penetrating Peptides (CPPs). The successful delivery of the Cre cargo in the animal experiments will be a significant milestone for the company and help with the commercial validation of the company’s biological peptides. It will enable the transition for proof of concept stage of validating their platform to the testing of therapeutic drug cargoes.
The company has an opportunity to improve their attractiveness of the platform by delivering a cargo class of interest into a target cell more efficiently than competitive technology. The company’s original CPP has already successfully delivered Cre into kidney cells. The company has also commenced further screening of their re-populated libraries to identify additional CPPs and has gained strong interest from biotech companies who are looking for effective delivery platforms for their developed drug cargoes.
About Phylogica Limited (ASX: PYC)
Phylogica’s drug delivery platform harnesses the power of viruses and bacteria for good. These organisms have long been known to cross the cell wall to where the highest value drug targets reside. Phylogica’s delivery technology uses their genetic secrets to take drug cargoes where they cannot go alone – unlocking the undruggable genome.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
